Exome Asset Management LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed December 13, 2024), Exome Asset Management LLC reported 59 stock positions worth $147.9 million. Its top holding was Eli Lilly (LLY) at 6.3% of the portfolio, followed by Ascendis Pharma A/S (ASND, 4.4%) and Bridgebio Pharma (BBIO, 3.6%). Compared with Q2 2024, it opened 30 new positions, sold out of 23, added to 14 and reduced 8. The biggest buy was a new position in Structure Therapeutics (GPCR) and the biggest sale an exit from Sarepta Therapeutics (SRPT).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0002011932
- Portfolio Value
- $147.9M (Q3 2024)
- SEC Filing
- 0001420506-24-002622 ↗ filed Dec 13, 2024
Holdings Value
Holdings 59 stocks · $147.9M
| LLY Eli Lilly & Co. | 6.26% | 10,447 | $9.3M | Add +7.7% |
| ASND Ascendis Pharma A/S | 4.43% | 43,849 | $6.5M | Add +119.3% |
| BBIO Bridgebio Pharma Inc. | 3.63% | 211,000 | $5.4M | Add +167.4% |
| GPCR Structure Therapeutics Inc. | 3.57% | 120,165 | $5.3M | New |
| TGTX TG Therapeutics Inc. | 3.28% | 207,627 | $4.9M | Reduce -17.5% |
| ALGN Align Technology Inc. | 3.21% | 18,700 | $4.8M | New |
| CI The Cigna Group | 2.86% | 12,200 | $4.2M | No change |
| GILD Gilead Sciences Inc. | 2.83% | 50,000 | $4.2M | New |
| GERN Geron Corp. | 2.78% | 905,126 | $4.1M | New |
| BNTX Biontech SE-ADR | 2.77% | 34,552 | $4.1M | New |
| BMY Bristol-Myers Squibb Co. | 2.73% | 78,000 | $4.0M | New |
| VRDN Viridian Therapeutics Inc. | 2.68% | 174,400 | $4.0M | New |
| ISRG Intuitive Surgical Inc. | 2.47% | 7,427 | $3.6M | Add +16.8% |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 2.32% | 15,300 | $3.4M | Reduce -53.9% |
| BPMC Blueprint Medicines Corp. | 2.29% | 36,700 | $3.4M | New |
| GKOS Glaukos Corp. | 2.28% | 25,857 | $3.4M | New |
| SWTX Springworks Therapeutics Inc. | 2.18% | 100,700 | $3.2M | New |
| IRON Disc Medicine Inc. | 2.14% | 64,516 | $3.2M | Add +5.8% |
| CYTK Cytokinetics Inc. | 2.09% | 58,583 | $3.1M | New |
| AGIO Agios Pharmaceuticals Inc. | 1.99% | 66,200 | $2.9M | New |
| RLAY Relay Therapeutics Inc. | 1.98% | 414,629 | $2.9M | New |
| APLS Apellis Pharmaceuticals Inc. | 1.96% | 100,367 | $2.9M | Add +114.0% |
| RDY Dr. Reddy's Laboratories-ADR | 1.95% | 36,300 | $2.9M | No change |
| NTRA Natera Inc. | 1.93% | 22,450 | $2.9M | Add +20.4% |
| BIIB Biogen Inc. | 1.74% | 13,317 | $2.6M | New |
| INSM Insmed Inc. | 1.66% | 33,600 | $2.5M | Reduce -40.9% |
| LEGN Legend Biotech Corp.-ADR | 1.55% | 47,000 | $2.3M | New |
| MERSANA THERAPEUTICS INC | 1.51% | 1,178,570 | $2.2M | New |
| ETNB 89BIO Inc. | 1.50% | 300,600 | $2.2M | New |
| AKRO Akero Therapeutics Inc. | 1.50% | 77,100 | $2.2M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 1.49% | 138,152 | $2.2M | Reduce -49.7% |
| STOK Stoke Therapeutics Inc. | 1.47% | 176,600 | $2.2M | New |
| AMGN Amgen Inc. | 1.46% | 6,700 | $2.2M | Reduce -43.2% |
| GH Guardant Health Inc. | 1.39% | 89,800 | $2.1M | Add +13.7% |
| NUVL Nuvalent Inc. Class A | 1.38% | 19,945 | $2.0M | New |
| RVNC Revance Therapeutics Inc. | 1.22% | 347,600 | $1.8M | New |
| KURA Kura Oncology Inc. | 1.19% | 90,305 | $1.8M | Reduce -31.4% |
| RZLT Rezolute Inc. | 1.15% | 352,056 | $1.7M | Add +24.7% |
| PLRX Pliant Therapeutics Inc. | 1.13% | 149,600 | $1.7M | Add +20.6% |
| EWTX Edgewise Therapeutics Inc. | 1.08% | 59,900 | $1.6M | New |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | 1.03% | 2,000,000 | $1.5M | New |
| STAA Staar Surgical Co. | 1.02% | 40,800 | $1.5M | New |
| TARS Tarsus Pharmaceuticals Inc. | 1.01% | 45,600 | $1.5M | New |
| BCRX Biocryst Pharmaceuticals Inc. | 1.01% | 196,500 | $1.5M | New |
| SRRK Scholar Rock Holding Corp. | 0.75% | 133,039 | $1.1M | New |
| TECX Tectonic Therapeutic Inc. | 0.74% | 36,344 | $1.1M | Add +12.2% |
| ALVO Alvotech SA | 0.72% | 90,100 | $1.1M | Reduce -9.0% |
| QTRX Quanterix Corp. | 0.64% | 73,501 | $953K | Add +23.2% |
| ESTA Establishment Labs Holdings | 0.63% | 21,700 | $939K | No change |
| ACRV Acrivon Therapeutics Inc. | 0.55% | 116,757 | $817K | New |
| LXEO Lexeo Therapeutics Inc. | 0.54% | 88,148 | $797K | New |
| VYNE THERAPEUTICS INC | 0.45% | 353,434 | $664K | No change |
| SYRS Syros Pharmaceuticals Inc. | 0.43% | 298,575 | $642K | Add +87.6% |
| ADAG Adagene Inc.-ADR | 0.39% | 262,625 | $583K | Add +74.1% |
| GOSS Gossamer Bio Inc. | 0.31% | 468,499 | $462K | Reduce -58.5% |
| APRE Aprea Therapeutics Inc. | 0.26% | 137,174 | $377K | No change |
| PROCF Sofgen Pharma SA filed as PROCAPS GROUP SA | 0.19% | 126,901 | $280K | No change |
| CYPH Cypherpunk Technologies Inc. filed as LEAP THERAPEUTICS INC | 0.18% | 102,631 | $264K | New |
| PACB Pacific Biosciences of Calif | 0.09% | 75,300 | $128K | No change |
Portfolio Sells Q2 2024 → Q3 2024
| SRPT Sarepta Therapeutics Inc. | Sold out | 0.00% | −4.63 |
| CRBP Corbus Pharmaceuticals Holdi | Sold out | 0.00% | −3.42 |
| TVTX Travere Therapeutics Inc. | Sold out | 0.00% | −3.24 |
| MDGL Madrigal Pharmaceuticals Inc. | Sold out | 0.00% | −2.69 |
| AVDL Avadel Pharmaceuticals Ltd. | Sold out | 0.00% | −2.62 |
| DXCM Dexcom Inc. | Sold out | 0.00% | −2.62 |
| AUTL Autolus Therapeutics PLC | Sold out | 0.00% | −2.60 |
| MRUS Merus NV | Sold out | 0.00% | −2.38 |
| MASI Masimo Corp. | Sold out | 0.00% | −2.22 |
| WVE Wave Life Sciences Ltd. | Sold out | 0.00% | −2.17 |
| CABA Cabaletta Bio Inc. | Sold out | 0.00% | −2.00 |
| ARVN Arvinas Inc. | Sold out | 0.00% | −1.95 |
| ONC Beone Medicines Ltd.-ADR | Reduce -53.9% | 2.32% | −1.90 |
| AMGN Amgen Inc. | Reduce -43.2% | 1.46% | −1.82 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −1.79 |
| INSM Insmed Inc. | Reduce -40.9% | 1.66% | −1.73 |
| FULC Fulcrum Therapeutics Inc. | Sold out | 0.00% | −1.67 |
| ATEC Alphatec Holdings Inc. | Sold out | 0.00% | −1.51 |
| ABCL Abcellera Biologics Inc. | Sold out | 0.00% | −1.36 |
| ZLAB Zai Lab Ltd.-ADR | Sold out | 0.00% | −1.34 |
| KURA Kura Oncology Inc. | Reduce -31.4% | 1.19% | −1.22 |
| ELEV Elevation Oncology Inc. | Sold out | 0.00% | −0.89 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -49.7% | 1.49% | −0.72 |
| TGTX TG Therapeutics Inc. | Reduce -17.5% | 3.28% | −0.70 |
| QTTB Q32 Bio Inc. | Sold out | 0.00% | −0.70 |
| GOSS Gossamer Bio Inc. | Reduce -58.5% | 0.31% | −0.59 |
| PMVP PMV Pharmaceuticals Inc. | Sold out | 0.00% | −0.52 |
| NBP Novabridge Biosciences | Sold out | 0.00% | −0.40 |
| ALVO Alvotech SA | Reduce -9.0% | 0.72% | −0.35 |
| HLVX Hillevax Inc. | Sold out | 0.00% | −0.23 |
| SGMT Sagimet Biosciences Inc. Class A | Sold out | 0.00% | −0.15 |
Portfolio Buys Q2 2024 → Q3 2024
| GPCR Structure Therapeutics Inc. | New | 3.57% | +3.57 |
| ALGN Align Technology Inc. | New | 3.21% | +3.21 |
| GILD Gilead Sciences Inc. | New | 2.83% | +2.83 |
| GERN Geron Corp. | New | 2.78% | +2.78 |
| BNTX Biontech SE-ADR | New | 2.77% | +2.77 |
| BMY Bristol-Myers Squibb Co. | New | 2.73% | +2.73 |
| VRDN Viridian Therapeutics Inc. | New | 2.68% | +2.68 |
| BPMC Blueprint Medicines Corp. | New | 2.29% | +2.29 |
| GKOS Glaukos Corp. | New | 2.28% | +2.28 |
| SWTX Springworks Therapeutics Inc. | New | 2.18% | +2.18 |
| CYTK Cytokinetics Inc. | New | 2.09% | +2.09 |
| ASND Ascendis Pharma A/S | Add +119.3% | 4.43% | +2.00 |
| AGIO Agios Pharmaceuticals Inc. | New | 1.99% | +1.99 |
| RLAY Relay Therapeutics Inc. | New | 1.98% | +1.98 |
| BBIO Bridgebio Pharma Inc. | Add +167.4% | 3.63% | +1.85 |
| BIIB Biogen Inc. | New | 1.74% | +1.74 |
| LEGN Legend Biotech Corp.-ADR | New | 1.55% | +1.55 |
| MERSANA THERAPEUTICS INC | New | 1.51% | +1.51 |
| ETNB 89BIO Inc. | New | 1.50% | +1.50 |
| AKRO Akero Therapeutics Inc. | New | 1.50% | +1.50 |
| STOK Stoke Therapeutics Inc. | New | 1.47% | +1.47 |
| NUVL Nuvalent Inc. Class A | New | 1.38% | +1.38 |
| RVNC Revance Therapeutics Inc. | New | 1.22% | +1.22 |
| EWTX Edgewise Therapeutics Inc. | New | 1.08% | +1.08 |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | New | 1.03% | +1.03 |
| STAA Staar Surgical Co. | New | 1.02% | +1.02 |
| TARS Tarsus Pharmaceuticals Inc. | New | 1.01% | +1.01 |
| BCRX Biocryst Pharmaceuticals Inc. | New | 1.01% | +1.01 |
| SRRK Scholar Rock Holding Corp. | New | 0.75% | +0.75 |
| ACRV Acrivon Therapeutics Inc. | New | 0.55% | +0.55 |
| LXEO Lexeo Therapeutics Inc. | New | 0.54% | +0.54 |
| APLS Apellis Pharmaceuticals Inc. | Add +114.0% | 1.96% | +0.35 |
| TECX Tectonic Therapeutic Inc. | Add +12.2% | 0.74% | +0.27 |
| CYPH Cypherpunk Technologies Inc. | New | 0.18% | +0.18 |
| NTRA Natera Inc. | Add +20.4% | 1.93% | +0.13 |
| RZLT Rezolute Inc. | Add +24.7% | 1.15% | +0.07 |
| ADAG Adagene Inc.-ADR | Add +74.1% | 0.39% | −0.02 |
| ISRG Intuitive Surgical Inc. | Add +16.8% | 2.47% | −0.05 |
| PLRX Pliant Therapeutics Inc. | Add +20.6% | 1.13% | −0.05 |
| QTRX Quanterix Corp. | Add +23.2% | 0.64% | −0.06 |
| SYRS Syros Pharmaceuticals Inc. | Add +87.6% | 0.43% | −0.30 |
| IRON Disc Medicine Inc. | Add +5.8% | 2.14% | −0.30 |
| GH Guardant Health Inc. | Add +13.7% | 1.39% | −0.64 |
| LLY Eli Lilly & Co. | Add +7.7% | 6.26% | −1.56 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 52 | $162.1M | GH, PRAX, TGTX, COGT, IONS |
| Q1 2026 | 45 | $169.9M | PRAX, COGT, ELVN, IONS, GH |
| Q4 2025 | 53 | $202.4M | PRAX, COGT, GH, IONS, LLY |
| Q3 2025 | 54 | $151.4M | IONS, CYTK, BBIO, COGT, GH |
| Q2 2025Amended | 55 | $121.3M | ISHARES TR, BBIO, GH, GERN, IONS |
| Q1 2025Amended | 49 | $111.6M | BBIO, GH, GERN, AZN, CYTK |
| Q4 2024 | 58 | $132.9M | BBIO, LLY, GERN, HUM, GH |
| Q3 2024Amended | 59 | $147.9M | LLY, ASND, BBIO, GPCR, TGTX |
| Q2 2024Amended | 52 | $112.3M | LLY, SRPT, ONC, TGTX, CI |
| Q1 2024 | 53 | $116.8M | LLY, RDY, ONC, CI, ALPN |